Brief: Biophytis: U.S. Centers To Restart Recruitment For COVA Phase 2-3 Study
15/11/2021 07:16
Nov 15 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS ANNOUNCES US CENTERS TO RESTART RECRUITMENT FOR
THE
COVA PHASE 2-3 STUDY WITH SARCONEOS (BIO101) IN COVID-19
* FDA CONFIRMED THAT, AS PART OF PROTOCOL AND FOLLOWING DMC
RECOMMENDATION, ENROLLMENT IN USA COULD RESTART
Source text for Eikon: ID:nEQ8v1n5wa
Further company coverage: ALBPS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon